Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Outstanding (2016 - 2025)

Ligand Pharmaceuticals' Shares Outstanding history spans 13 years, with the latest figure at $17.0 million for Q4 2022.

  • For Q4 2022, Shares Outstanding rose 1.1% year-over-year to $17.0 million; the TTM value through Dec 2022 reached $17.0 million, up 1.1%, while the annual FY2022 figure was $17.0 million, 1.1% up from the prior year.
  • Shares Outstanding for Q4 2022 was $17.0 million at Ligand Pharmaceuticals, up from $16.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $21.3 million in Q1 2018 and bottomed at $16.0 million in Q1 2020.
  • The 5-year median for Shares Outstanding is $16.8 million (2019), against an average of $17.9 million.
  • The largest annual shift saw Shares Outstanding fell 18.98% in 2019 before it rose 4.27% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $20.8 million in 2018, then dropped by 18.98% to $16.8 million in 2019, then dropped by 4.42% to $16.1 million in 2020, then rose by 4.27% to $16.8 million in 2021, then grew by 1.1% to $17.0 million in 2022.
  • Per Business Quant, the three most recent readings for LGND's Shares Outstanding are $17.0 million (Q4 2022), $16.9 million (Q1 2022), and $16.8 million (Q4 2021).